S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

ARQT Arcutis Biotherapeutics Inc

8.79

-0.05 (-0.57%)

Last Updated: 12:53:51

Delayed by 15 minutes

Unknown (sec Staff)

This regulatory filing also includes additional resources:
filename1.pdf

Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Arcutis Biotherapeutics Charts.

Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Arcutis Biotherapeutics Charts.

Arcutis Biotherapeutics, Inc. News

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Monday 29 April 2024 (3 days ago) • GlobeNewswire Inc.

Arcutis Appoints David Topper as Chief Financial Officer
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Friday 5 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Thursday 28 March 2024 (1 month ago) • GlobeNewswire Inc.

Arcutis Promotes Todd Tucker to Chief Human Resources Officer
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Sunday 10 March 2024 (2 months ago) • GlobeNewswire Inc.

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
Saturday 9 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 5 March 2024 (2 months ago) • GlobeNewswire Inc.

More Arcutis Biotherapeutics, Inc. News Articles

Atacama Resources (PK)

NaturalShrimp (QB)

Verb Technology

Mullen Automotive

BlackStar Enterprise (PK)

International Star (PK)

MicroCloud Hologram

Moon Equity (PK)

Globestar Therapeutics (PK)

Virexit Technologies (PK)

FuelCell Energy

Seven Arts Entertainment (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions